Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States.

Drazer MW, Huo D, Schonberg MA, Razmaria A, Eggener SE.

J Clin Oncol. 2011 May 1;29(13):1736-43. doi: 10.1200/JCO.2010.31.9004. Epub 2011 Mar 28.

2.

Medical center characteristics associated with PSA screening in elderly veterans with limited life expectancy.

So C, Kirby KA, Mehta K, Hoffman RM, Powell AA, Freedland SJ, Sirovich B, Yano EM, Walter LC.

J Gen Intern Med. 2012 Jun;27(6):653-60. doi: 10.1007/s11606-011-1945-9. Epub 2011 Dec 17.

3.

Clinician Factors Associated With Prostate-Specific Antigen Screening in Older Veterans With Limited Life Expectancy.

Tang VL, Shi Y, Fung K, Tan J, Espaldon R, Sudore R, Wong ML, Walter LC.

JAMA Intern Med. 2016 May 1;176(5):654-61. doi: 10.1001/jamainternmed.2016.0695.

4.

National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.

Drazer MW, Huo D, Eggener SE.

J Clin Oncol. 2015 Aug 1;33(22):2416-23. doi: 10.1200/JCO.2015.61.6532. Epub 2015 Jun 8.

PMID:
26056181
5.

National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.

Drazer MW, Prasad SM, Huo D, Schonberg MA, Dale W, Szmulewitz RZ, Eggener SE.

Cancer. 2014 May 15;120(10):1491-8. doi: 10.1002/cncr.28600. Epub 2014 Feb 12.

6.

PSA screening among elderly men with limited life expectancies.

Walter LC, Bertenthal D, Lindquist K, Konety BR.

JAMA. 2006 Nov 15;296(19):2336-42.

PMID:
17105796
7.

Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.

Jemal A, Fedewa SA, Ma J, Siegel R, Lin CC, Brawley O, Ward EM.

JAMA. 2015 Nov 17;314(19):2054-61. doi: 10.1001/jama.2015.14905.

PMID:
26575061
8.

Cancer screening rates in individuals with different life expectancies.

Royce TJ, Hendrix LH, Stokes WA, Allen IM, Chen RC.

JAMA Intern Med. 2014 Oct;174(10):1558-65. doi: 10.1001/jamainternmed.2014.3895.

PMID:
25133746
9.

Prostate carcinoma among men with human immunodeficiency virus infection.

Crum NF, Spencer CR, Amling CL.

Cancer. 2004 Jul 15;101(2):294-9.

10.
11.

Cancer surveillance using registry data: Results and recommendations for the Lithuanian national prostate cancer early detection programme.

Gondos A, Krilaviciute A, Smailyte G, Ulys A, Brenner H.

Eur J Cancer. 2015 Aug;51(12):1630-7. doi: 10.1016/j.ejca.2015.04.009. Epub 2015 Jun 1.

PMID:
26044924
12.

Primary care providers' perspectives on discontinuing prostate cancer screening.

Pollack CE, Platz EA, Bhavsar NA, Noronha G, Green GE, Chen S, Carter HB.

Cancer. 2012 Nov 15;118(22):5518-24. doi: 10.1002/cncr.27577. Epub 2012 Apr 19.

13.

Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists.

Fowler FJ Jr, Bin L, Collins MM, Roberts RG, Oesterling JE, Wasson JH, Barry MJ.

Am J Med. 1998 Jun;104(6):526-32.

PMID:
9674714
14.

Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.

Tawfik A.

Ont Health Technol Assess Ser. 2015 May 1;15(11):1-37. eCollection 2015. Review.

16.

To be screened or not to be screened? Modeling the consequences of PSA screening for the individual.

Wever EM, Hugosson J, Heijnsdijk EA, Bangma CH, Draisma G, de Koning HJ.

Br J Cancer. 2012 Aug 21;107(5):778-84. doi: 10.1038/bjc.2012.317. Epub 2012 Jul 17.

17.

Prostate-specific antigen screening for prostate cancer in older men in the United States of America.

Black A, Berg CD.

Gerontology. 2012;58(4):331-6. doi: 10.1159/000334242. Epub 2012 Feb 16.

18.

Probability of an abnormal screening prostate-specific antigen result based on age, race, and prostate-specific antigen threshold.

Espaldon R, Kirby KA, Fung KZ, Hoffman RM, Powell AA, Freedland SJ, Walter LC.

Urology. 2014 Mar;83(3):599-605. doi: 10.1016/j.urology.2013.10.051. Epub 2014 Jan 16.

19.

National evidence on the use of shared decision making in prostate-specific antigen screening.

Han PK, Kobrin S, Breen N, Joseph DA, Li J, Frosch DL, Klabunde CN.

Ann Fam Med. 2013 Jul-Aug;11(4):306-14. doi: 10.1370/afm.1539.

20.

Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trial.

Barocas DA, Grubb R 3rd, Black A, Penson DF, Fowke JH, Andriole G, Crawford ED.

Cancer. 2013 Jun 15;119(12):2223-9. doi: 10.1002/cncr.28042. Epub 2013 Apr 4.

Supplemental Content

Support Center